- Home
- About Us
- Industry
- Services
- Reading
- Contact Us
Author: Vikas Kumar
March 13, 2023
Global Viral and Non-Viral Vector Manufacturing market is expected to register a CAGR of approx. 19% over the period of 2022-2028. Viral vector manufacturing refers to the process of producing viral particles (typically viruses that have been modified) used as a delivery system for therapeutic genes. Non-viral vector manufacturing refers to the production of non-viral particles (such as nanoparticles, liposomes, or plasmids) used for gene delivery. Both methods aim to deliver therapeutic genes to target cells, but non-viral methods are generally considered safer and less immunogenic. The global viral and non-viral vector manufacturing market is growing due to the growth of the biotechnology industry, especially in the field of regenerative medicine and the use of vectors as delivery systems in gene therapy around the globe. For instance, According to the Biotechnology Innovation Organization (BIO), the biotechnology industry in North America has experienced significant growth in recent years. In 2021, the biotechnology industry in North America generated approximately $600 billion in revenue.In 2021, North American biotechnology companies invested over $70 billion in R&D activities. Owing to these glaring statistics the demand for viral and non-viral vector manufacturing is anticipated to grow in the forthcoming years as the increasing research and development and funding in the manufacturing of vectors in the biotech industry thus boosted the growth of the viral and non-viral vector manufacturing industry. Moreover, the increasing prevalence of chronic diseases, such as cancer and genetic disorders and advancements in genetic engineering is fueling the demand for the viral and non-viral vector manufacturing market. Furthermore, an increasing number of clinical trials using vector-based therapies and growing interest in regenerative medicine are expected to drive the market for viral and non-viral vector manufacturing market in the coming years.
Request for Sample of the report browse through- https://univdatos.com/get-a-free-sample-form-php/?product_id=35478
Based on the vector type, the viral and non-viral vector manufacturing market is segmented into a viral vector and non-viral vectors. The non-viral vectors segment accounted for a significant market share in 2021 and it is estimated that it will grow rapidly during the projected timeframe. Non-viral vectors are considered safer than viral vectors, as they do not contain live viruses and are less likely to cause immune reactions or other adverse events. they are typically easier to produce than viral vectors, which can help reduce the cost of production and can be used in a wide range of applications, including gene therapy, vaccine development, and research.
Based on the disease, the market is fragmented into cancer, genetic disease, infectious disease, cardiovascular disease, and others. The cancer segment grabbed a considerable market share in 2021, and it is expected to grow at a significant CAGR during the forecast period. An increase in the adoption of vectors for the development of cancer therapies, a large number of research programs, and recent approvals of gene therapy products led to the growth of the segment.
For a better understanding of the market adoption of viral and non-viral vector manufacturing, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, France, Italy, Spain, U.K., and Rest of Europe), Asia-Pacific (China, Japan, India, Australia, and Rest of APAC), and Rest of World. North America constitutes a major market for the viral and non-viral vector manufacturing industry owing to the growing search and development as well as growing investment in the biotechnology sector. Moreover, the growing elderly population as well as the large patient population, including individuals with rare diseases and cancer who may benefit from vector-based therapies, increasing the demand for viral and non-viral vector manufacturing market. For instance, in 2021, According to the World Health Organization (WHO), the number of people aged 60 years and older is projected to double by 2050, with North America having a significant share of this ageing population. Owing to these glaring statistics the increase in the demand for healthcare services, including vector-based therapies is one of the major factors expanding the growth of the market. Additionally, a favourable regulatory environment for the development and commercialization of vector-based therapies well-developed healthcare infrastructure provides a favourable environment for the development and commercialization of vector-based therapies in the region.
For a detailed analysis of the Global Viral and Non-Viral Vector Manufacturing Market browse through– https://univdatos.com/report/viral-and-non-viral-vector-manufacturing-market/
Some of the major players operating in the market include Boehringer Ingelheim International GmbH, Catalent Inc, FUJIFILM Holdings Corporation, Thermo Fisher Scientific Inc, Lonza Group AG, Merck KGaA, Oxford BioMedica plc, Sartorius AG, TAKARA BIO INC, and WuXi AppTec Co Ltd.
Global Viral and Non-Viral Vector Manufacturing Market Segmentation
Market Insight, by Vector Type
Market Insight, by Disease
Market Insight, by Application
Market Insight, by Region
Top Company Profiles
Get a Callback
By submitting this form, I understand that my data will be processed by Univdatos as indicated above and described in the Privacy Policy. *